摘要
目的探讨低分子肝素与小剂量尿激酶治疗进展性脑卒中的临床效果。方法分析该院收治的进展性脑卒中患者临床资料进行分析汇总,依据治疗方式不同分为治疗Ⅰ组(低分子肝素治疗组)和治疗Ⅱ组(小剂量尿激酶治疗组)各30例,对两组疗效进行分析。结果治疗Ⅰ组临床治疗总有效率稍高于治疗Ⅱ组,差异均有统计学意义(P<0.05)。结论低分子肝素在治疗进展性脑卒中方面疗效显著,预后良好,值得临床借鉴应用。
Objective To study the comparative effectiveness of low molecular weight heparin with low-dose urokinase treatment of stroke in progression. Methods The analysis of the clinical data of progressive stroke patients in our hospital for analysis summary according to the treatment were divided into treatment group I and treatment group Ⅱ nd 30 cases,The two groups were analyzed. Results The Results of the clinical treatment of the treatment group Ⅰ total efficiency slightly higher than the treatment group Ⅱ （P 〈0.05） differences were statistically significant. Conclusion The low molecular weight heparin in the treatment of patients with progressive stroke efficacy significantly,the prognosis is good,and worthy to learn from the application.
出处
《中外医疗》
2013年第2期101-101,103,共2页
China & Foreign Medical Treatment
关键词
低分子肝素
小剂量尿激酶
进展性脑卒中
Low molecular weight heparin
Small doses of urokinase
Progressive stroke
